Abstract
Objective: The Japanese drug use system allowed the “once-daily use” of inhaled corticosteroid (ICS) fluticasone furoate (FF) combined with a long acting beta-2 agonist (LABA) vilanterol (VI) again...
Highlights
Asthma is defined by a history of respiratory symptoms including wheezing, shortness of breath, chest tightness, and cough that vary over time and in intensity, together with variable expiratory airflow limitation (Global Initiative for Asthma (GINA), 2018; World Health Organization)
The most striking finding in this study is the prominent increase in airflow data of peak flow, V75, V50 and maximum mid-expiratory flow rate (MMF), by the treatment switch from previous drugs to fluticasone furoate (FF)/VI
There were significant increases in FEV1, %vital capacity (VC), inspiratory reserve volume (IRV), and asthma control test (ACT) score the increase in V25 or FEV1/forced vital capacity (FVC) was statistically insignificant
Summary
Asthma is defined by a history of respiratory symptoms including wheezing, shortness of breath, chest tightness, and cough that vary over time and in intensity, together with variable expiratory airflow limitation (Global Initiative for Asthma (GINA), 2018; World Health Organization). This condition is due to inflammation of the air passages in the lungs (World Health Organization). The Japanese drug use system approved the use of beclomethasone dipropionate, an ICS, for the first time in 1978 This first-generation ICS needed to be used four-times daily. The Japanese drug use system approved a second ICS, fluticasone propionate (FP), in 1998 and a third ICS, budesonide, in 2002, which needed to be used twice-daily
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
